|
|
Thermo Fisher Scientific Inc (NYSE: TMO) |
|
Price: $519.9000
$2.18 
0.421%
|
| Day's High:
| $526.805
| Week Perf:
| -0.31 %
|
| Day's Low: |
$ 517.13 |
30 Day Perf: |
-2.38 % |
| Volume (M): |
1,100 |
52 Wk High: |
$ 627.88 |
| Volume (M$): |
$ 571,838 |
52 Wk Avg: |
$565.58 |
| Open: |
$520.79 |
52 Wk Low: |
$493.30 |
|
|
| Market Capitalization (Millions $) |
199,248 |
| Shares
Outstanding (Millions) |
383 |
| Employees |
122,000 |
| Revenues (TTM) (Millions $) |
42,879 |
| Net Income (TTM) (Millions $) |
6,338 |
| Cash Flow (TTM) (Millions $) |
-4,057 |
| Capital Exp. (TTM) (Millions $) |
1,400 |
Thermo Fisher Scientific Inc
Thermo Electron Corporation is a world leader in high-tech instruments. The company
helps life science, laboratory, and industrial customers advance scientific knowledge,
enable drug discovery, improve manufacturing processes, and protect people and
the environment with instruments, scientific equipment, services, and software
solutions. The companys powerful technologies help researchers make discoveries
that will fight disease or prolong life. They automatically monitor and control
online production to ensure the quality and safety of raw materials as well as
the end products. And they are critical components embedded as enabling technologies
within scientific and industrial devices.
Our strategy going forward is to focus on internal growth by pursuing developments
in the markets that we serve that have potential for high growth. Our strategy
is also to continue to improve productivity, enabling us to better serve our
customers with improved products, technologies, and complete integrated systems
and services. In addition, we plan to augment that growth with strategic acquisitions
that expand the reach of our technology by either rounding out our product lines
or bringing them to new markets.
We report our business in two principal segments: Life and Laboratory Sciences,
Measurement and Control.
Competition
Life and Laboratory Sciences
Bioscience Technologies. In the markets served by this division, our principal
competitors include Eppendorf AG; Gilson, Inc.; Tecan Group Ltd.; PerkinElmer,
Inc.; Molecular Devices Corp.; Kendro Laboratory Products (a subsidiary of SPX
Corporation); and Beckman Coulter, Inc.
Scientific Instruments. In the markets served by this division, our principal
competitors include Applied Biosystems Inc.; Agilent Technologies Inc.; Waters
Corporation; Shimadzu Corporation; PerkinElmer; Bruker Daltonics Inc.; Hitachi,
Ltd.; and Varian Inc.
Informatics and Services. In the markets served by this division, our principal
competitors include PerkinElmer; Applied Biosystems; Beckman Coulter; Agilent;
and LabVantage Solutions.
Clinical Diagnostics. In the markets served by this division, our principal
competitors include Leica Microsystems; Sakura Finetechnical Co., Ltd.; Becton,
Dickinson and Company; Quidel Corporation; and Roche-Boeringher Manheim.
Measurement and Control
Process Instruments. In the markets served by this division, our principal
competitors include Mettler-Toledo International Inc.; Yokogawa Electric Corporation;
Fisher-Rosemount (a division of Emerson Electric Co., Inc.); Asea Brown Boveri
(Holding) Ltd.; Endress & Hauser; Integrated Measurement Systems, Inc.;
and Antek Instruments, Inc.
Environmental Instruments. In the markets served by this division, our principal
competitors include Danaher Corporation; Mettler-Toledo; Horiba; Fisher-Rosemount;
Teledyne Advanced Pollution Instrumentation, Inc.; RAE Systems Inc.; ISC; Canberra
Industries, Inc.; synOdys Group; GE Interlogix; and Smiths- Barringer.
Control Technologies. In the markets served by this division, our principal
competitors include SMC; Lytron Inc.; Julabo; TA Instruments; Gottfert; Brabender;
and MDC.
Company Address: 168 Third Avenue Waltham 2451 MA
Company Phone Number: 622-1000 Stock Exchange / Ticker: NYSE TMO
|
|
|
Customers Net Income grew by |
TMO's Customers Net Profit Margin grew to |
15.34 % |
6.69 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Thermo Fisher Scientific Inc
By
As I look back on the financial results for Thermo Fisher Scientific Inc. (NYSE: TMO) for the second quarter of 2024, I'm struck by the complexities of navigating a report that, at first glance, appears somewhat contradictory. While the company reported a slight decline in revenue?down 1.366% year-over-year, totaling $10.54 billion?there?s a silver lining in the earnings per share (EPS) figure, which rose an impressive 15% to $4.04.
This duality is not uncommon in the current economic landscape, where companies are often faced with fluctuating revenues but can still bolster their profitability through stringent cost management and effective operational strategies. Thermo Fisher's ability to increase its EPS from the preceding quarter (which stood at $3.46) is a testament to its resilient business model. In fact, the net profits jumped to $1.55 billion, reflecting a 14.02% year-over-year increase from $1.36 billion last year.
Another key highlight from the report is the company?s improved profit margins. With the net margin edging up to 14.73% and the operating margin rising to 17.27%, it?s clear that Thermo Fisher is not just a company that excels in revenue generation, but also one that understands the importance of maintaining an efficient cost structure. Operating earnings increased by 15.34% to $1.82 billion, showcasing the effectiveness of their strategies.
|
| Dividend
Published Mon, Jul 15 2024 7:45 AM UTC
Thermo Fisher Scientific Announces Quarterly Dividend Increase, Empowering Shareholders Amidst Strong Financial Performance
WALTHAM, Mass. - Thermo Fisher Scientific Inc. (NYSE: TMO), the global leader in serving science, has recently declared an increase in its quarterly cash dividend, demonstrating their commitment to creating value for shareholders. The company s Boar...
|
| Dividend
Published Sun, Jul 14 2024 7:36 AM UTC
In the latest news from Thermo Fisher Scientific, the company has declared a quarterly cash dividend of $0.39 per common share, to be paid on October 15, 2024, to shareholders of record as of September 13, 2024. Thermo Fisher Scientific is a world leader in serving science, with annual revenue exceeding $40 billion. However, Thermo Fisher Scientific Inc stock has seen a drop...
|
| Dividend
Published Fri, Jul 12 2024 4:42 AM UTC
Thermo Fisher Scientific Inc. Declares Quarterly Dividend: A Reliable Investment Opportunity in the Science Industry
Thermo Fisher Scientific Inc. (NYSE: TMO) has announced a quarterly cash dividend of $0.39 per common share, which will be payable on October 15, 2024, to shareholders of record as of September 13, 2024. With annual revenue exceeding $40 billion, Thermo Fi...
|
| Merger and Acquisition
Published Mon, Jul 8 2024 11:38 AM UTC
Breaking News - UPPSALA, Sweden, July 08, 2024: Olink Holding AB (publ) (Nasdaq: OLK) announced today that the UK Competition and Markets Authority (CMA) has unconditionally approved the tender offer by Orion Acquisition AB, a wholly owned subsidiary of Thermo Fisher Scientific Inc., for all outstanding Common Shares and American Depositary Shares of Olink at $26.00 per...
|
| Per Share |
Current |
| Earnings (TTM) |
16.54 $ |
| Revenues (TTM) |
111.88 $
|
| Cash Flow (TTM) |
- |
| Cash |
14.53 $
|
| Book Value |
129.29 $
|
| Dividend (TTM) |
1.52 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
16.54 $
|
| Revenues (TTM) |
111.88 $ |
| Cash Flow (TTM) |
- |
| Cash |
14.53 $
|
| Book Value |
129.29 $ |
| Dividend (TTM) |
1.52 $ |
|
|
| |
| North America |
|
 52.76 % |
of total Revenue |
| Europe |
|
25.34 % |
of total Revenue |
| Asia-Pacific |
|
18.14 % |
of total Revenue |
| Other regions |
|
3.75 % |
of total Revenue |
| Consumables |
|
41.32 % |
of total Revenue |
| Instruments |
|
16.69 % |
of total Revenue |
| Services |
|
41.99 % |
of total Revenue |
| Total Reportable Life Sciences Solutions |
|
22.52 % |
of total Revenue |
| Total Reportable Analytical Instruments |
|
17.06 % |
of total Revenue |
| Total Reportable Specialty Diagnostics |
|
10.65 % |
of total Revenue |
| Total Reportable Laboratory Products and Biopharma Services |
|
54.16 % |
of total Revenue |
| Eliminations |
|
-4.41 % |
of total Revenue |
| Reconciling Items |
|
-0.08 % |
of total Revenue |
| United States |
|
51.01 % |
of total Revenue |
| Other |
|
48.99 % |
of total Revenue |
|
|
4.96%